

AREA PRESCRIBING COMMITTEE – ACTION LIST 14th APRIL 2016

Action Reference	Minute Reference	ACTION	OWNER	FURTHER COMMENTS	TARGET DATE	STATUS (R/A/Clear)
14/050	134/14	Add second line use of anti-TNFs for psoriatic arthritis in line with the decisions of the IFR panel.	LA	To be added to Blueteq	16.06.2016	RED ONGOING
ACTIONS FOR 2015						
15/42	26/15	Lothian Annual Declaration of Interest Form To be developed and completed annually by committee members.	LA		16.06.2016	ONGOING
15/34	72/15	NG 14-Melanoma – assessment & management	LA BG PB	Vitamin D guidelines are under review, working group to be set up including MO team BG (NCUHT) and PB (UHMBT) to review and update all current guidelines, to be brought to June 2016 meeting after approval at the relevant Medicine Management Trust groups	16.06.2016	ONGOING
15/39	111/15	Sulfasalazine SCG Review for gastro indications.	PB	It was agreed that monitoring frequency should be the same for all patients. Amended document to be brought to June meeting	16.06.2016	ONGOING
15/43	126/15	Azathioprine & Mercaptopurine SCG To be reviewed in light of gastroenterologist comments.	LA	LA to review the SCG taking comments from Mr Dennis Burke and Dr Shadad (both NCUHT) into account	16.06.2016	ONGOING
15/53	143/15b	Prescribing review: LHRH Agonists	BG PB	Comments on recommendation 2 & 3 to be brought back to next meeting.	16.06.2016	ONGOING
02/16	02/16	Review of COPD guidance	BG	Amended documents to be brought to the next meeting. Decision deferred to next meeting	16.06.2016	ONGOING

03/16	03/16	Lothian Joint Formulary review Working group to be set up to discuss the options for formulary in light of discrepancies between Lothian and NICE.	LA	The Committee asked that LA lead the task and finish group and produce an action plan for the next meeting. It was agreed that the group should aim for the portal to be live by October 16	16.06.2016	ONGOING
04/16	08/16	NICE MO Baseline Assessment	AL	AL to share transfer of care audit at the next meeting of the LPN	16.06.2016	ONGOING
05/16	11/16	NOAC Guidance Comment was made on the 1 st Care Cumbria “AF – which NOAC to use” document around its convenience however evidence and references to be provided and drug choices should be in line with NICE guidance.	AM	AM to ask the author to provide this for April meeting. Nothing received to date.	16.06.2016	ONGOING
07/16	14/16	STOPP START Toolkit	ALL	No comments were received from committee members. Final draft now in production incorporating comments from NICE associates network, to be bought to next meeting	16.06.2016	ONGOING
08/16	15/16	Dapsone SCG	PB	Final version to next meeting	16.06.2016	ONGOING
09/16	18/16 33/16	Memantine in combination with AChE RAG status review	HH	The committee requested that the SCP is redrafted to with the requested changes and bought to next meeting.	16.06.2016	ONGOING
10/16	19/16	Insulin Passport	HH	HH to ask Cumbria Diabetes what they recommend.	16.06.2016	ONGOING
14/16	32/16	Acetyl cholinesterase inhibitors – SCG review	HH	The committee requested some changes to align with NICE TA217 and to include an annual cognitive review by secondary care. Final version to be bought to next meeting.	16.06.2016	

15/16	40/16	DRUG SAFETY UPDATE – Feb 16	LA	Points 1 & 2 add to Prescription Pad	16.06.2016	
16/16	43/16	Alimemazine	HH	Review of RAG status of alimemazine following requests by community paediatrician	16.06.2016	
17/16	44/16	Ulipristal	PB	Bring LMMG review to next meeting	16.06.2016	